Leveraging the availability of peripheral blood samples and tumor samples obtained from distinct metastatic deposits spanning treatment-naive progression on-PD-1 inhibitor and progression post-PD-1 inhibitor time points (Fig. 1a), the temporal dynamics of the T-cell repertoire were evaluated. The gene discussed is PDCD1; the disease is neoplasm.